APPROVED for adults
with prurigo nodularis (PN)
For first-line use regardless of
disease severity or prior
medication use for PN1
DUPIXENT was studied in 2 pivotal trials of adult patients with prurigo nodularis
≈3X
as many patients in PRIME
had significantly reduced itch at
Week 24 (60% with DUPIXENT
vs 18% with placebo; P<0.001,
primary endpoint)1,2
PRIME2
37% of DUPIXENT patients achieved a meaningful
response at Week 12 vs 22% with placebo; P=0.022
(primary endpoint). At Week 24, 58% of DUPIXENT
patients achieved significant itch relief vs 20% with
placebo; P<0.001 (secondary endpoint)1,2
≈2.5X
as many patients in PRIME achieved
significant nodule clearance
(IGA PN-S 0 or 1) at Week 24
(48% with DUPIXENT vs 18% with
placebo; P<0.001, secondary endpoint)1,2
PRIME2
45% of DUPIXENT patients similarly achieved
significant nodule clearance (IGA PN-S 0 or 1) at
Week 24 vs 16% with placebo; P<0.001
(secondary endpoint)1,2
IGA PN-S, Investigator’s Global
Assessment PN-Stage.
DUPIXENT HAS A DEMONSTRATED
SAFETY PROFILE1
Most common adverse reactions in adult patients with prurigo nodularis (incidence ≥2%) are
nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea
The First and Only Therapy to Target IL‑4Rα, SPECIFICALLY
Inhibiting IL‑4 and IL‑13 Signaling1,3
The mechanism of dupilumab action has not been definitively established
Other attributes
NOT AN IMMUNOSUPPRESSANT
OR A STEROID1
NO INITIAL LAB TESTING OR
ONGOING LAB MONITORING
according to the Prescribing Information1
NO KNOWN DRUG‑TO‑DRUG
INTERACTIONS1
- Not metabolized through the liver or
excreted through the kidneys
NO boxed warning1
Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information below.
Select Important Safety Information
Warnings and Precautions
- Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions,
angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically
significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT
Discover how DUPIXENT inhibits IL-4
and IL-13 signaling
APPROVED FOR ADULTS WITH PRURIGO NODULARIS (PN)
Help appropriate patients benefit from DUPIXENT
Extensive Real-World
Experience
In the US,
studied in 17 pivotal trials
across 5indications1
Globally,
≈800,000
patients on
DUPIXENT therapy
worldwide
across 5 indications4,c,d
patients on
DUPIXENT therapy
worldwide
across 5 indications4,c,d
AD, atopic dermatitis.
aIQVIA NBRx data as of March 2024.
bFDA approved for uncontrolled moderate-to-severe AD since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years), and 2022 for infants to preschoolers (aged 6 months to 5 years).
cThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this worldwide patient number. Data through December 2023.
d≈493,000 US patients (new adult and pediatric patients 6+ months of age with uncontrolled moderate-to-severe AD) have filled at least 1 DUPIXENT prescription based on IQVIA National Source of Business (NSOB) data as of March 2024.
Extensive Real-World
Experience ACROSS DUPIXENT
In the us, studied in 17 pivotal trials across 5 indications2
Globally,
≈800,000
patients on DUPIXENT
therapy across 5
indications3,a
aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this worldwide patient number. Data through December 2023.
DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.